Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
2,299 people get ISIS articles and Market Currents by email alert.
Get email alerts on ISIS »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
PR Newswire (May 13, 2013)
-
-
PR Newswire (May 9, 2013)
-
PR Newswire (May 9, 2013)
-
-
PR Newswire (May 8, 2013)
-
PR Newswire (May 7, 2013)
-
PR Newswire (May 7, 2013)
-
-
PR Newswire (May 2, 2013)
-
-
PR Newswire (Apr 23, 2013)
-
PR Newswire (Apr 22, 2013)
-
-
-
To learn more about Seeking Alpha Pro, click here.
-
-
-
-
-
-
-
-
-
-
-
-
-
Isis Heads SouthRx Stocks • Wed, Oct 17, 2012 -
-
-
-
-
-
-
Isis Loss WidensZacks Investment Research • Tue, Aug 17, 2010
-
PR Newswire (May 13, 2013)
-
PR Newswire (May 9, 2013)
-
PR Newswire (May 9, 2013)
-
PR Newswire (May 8, 2013)
-
PR Newswire (May 7, 2013)
-
PR Newswire (May 7, 2013)
-
PR Newswire (May 2, 2013)
-
PR Newswire (Apr 23, 2013)
-
PR Newswire (Apr 22, 2013)
-
PR Newswire (Apr 8, 2013)
-
at CNBC.com (Apr 3, 2013)
-
PR Newswire (Apr 3, 2013)
-
PR Newswire (Mar 22, 2013)
-
PR Newswire (Mar 15, 2013)
-
PR Newswire (Mar 14, 2013)
-
PR Newswire (Mar 6, 2013)
ISIS vs. ETF Alternatives
Company Description
We are the leading company in antisense technology, exploiting a novel drug discovery platform we created to generate a broad pipeline of first-in-class drugs. Antisense technology is a direct route from genomics to drugs. With our highly efficient and prolific drug discovery platform we can... More
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Thursday, May 9, 6:47 AM Isis Pharmaceuticals (ISIS) falls 2.5% premarket, adding to yesterday's double-digit losses after pricing its previously announced public offering at $19 per share, 3.4% below yesterday's close. Comment! [Healthcare, On the Move]
- Tuesday, May 7, 7:41 PM Even more from Isis Pharmaceuticals (ISIS) following earnings: The company announces a 9M share public offering. The deal's underwriters will have the option to buy an additional 1.35M shares. (PR) 4 Comments [Healthcare]
- Tuesday, May 7, 7:36 PM More on Isis Pharmaceuticals' (ISIS) Q1 earnings: Revenues miss but results show Y/Y improvement on milestone payments of $7.5M from GlaxoSmithKline (Phase 2/3 ISIS-TTR) and $25M from Genzyme (NDA filing) — more milestone payments are on the horizon. The company sounds confident regarding the pipeline (recall BMO's positive outlook), calling it "robust" and promising to report "numerous events throughout the year." ISIS also says it is excited to update investors on KYNAMRO going forward. Shares -0.64% AH. (PR) Comment! [Earnings, Healthcare]
- Tuesday, May 7, 7:15 PM Isis Pharmaceuticals (ISIS): Q1 EPS of $-0.02 (in line). Revenue of $43.4M misses by $1.84M. (PR) Comment! [Earnings, Healthcare]
- Monday, May 6, 7:52 AM Isis Pharmaceuticals (ISIS) initiates Phase 1b/2a clinical study — via licensing partner AstraZeneca (AZN) — of its antisense drug ISIS-STATRx in HCC patients. The effort is part of a broader initiative to study the drug in a number of different cancers. For more on ISIS' antisense technology, see SA contributor Jane Edmondson's recent writeup. (PR) Comment! [Healthcare]
- Tuesday, April 23, 7:51 AM Isis Pharmaceuticals (ISIS) initiates a Phase 2 study of ISIS-SMNRx in infants with spinal muscular atrophy. The company will get $3.5M from Biogen (BIIB) upon dosing the first infant next month. Comment! [Healthcare]
- Friday, April 19, 3:41 PM Isis Pharmaceuticals (ISIS +8.4%) enjoys a strong session after BMO reiterates its Outperform rating and raises its price target to $31 from $22 citing a meeting with the company's SVP of Clinical Development regarding ISIS' antisense oligonucleotide pipeline. Separately, ISIS renews its lab testing agreement with Ontario-based CML HealthCare. Comment! [Healthcare, On the Move]
- Monday, April 8, 9:26 AM Isis Pharmaceuticals (ISIS) forms an alliance with Roche (RHHBY.OB) to utilize Isis' technology to develop innovative treatments for Huntington's disease. The companies will look to advance Isis' lead drug candidate which works by blocking the huntingtin protein. Isis will receive an upfront payment of $30M and may reap $362M in milestone payments and licensing fees going forward. 1 Comment [Healthcare]
- Wednesday, April 3, 8:35 AM Isis Pharmaceuticals (ISIS) says it has initiated a Phase 1 study of its atherosclerosis drug ISIS-APOARx. The drug curtails the production of lipoprotein (a) which, when present at high levels, increases the risk of heart attack and stroke. Comment! [Healthcare]
- Friday, March 22, 4:10 PM Isis Pharmaceuticals (ISIS -6.1%) becomes a casualty of the European Medicines Agency today, as the committee confirmed its previous position and maintained a negative opinion on the marketing authorization application for Kynamro as a treatment for patients with Homozygous Familial Hypercholesterolaemia. 2 Comments [Healthcare, Global & FX, On the Move]
- Wednesday, March 13, 8:21 AM Isis' (ISIS) CRPRx drug performed well in a Phase I trial, cutting the C-reactive protein in healthy subjects. "Selective reduction of CRP could offer a safer approach to treating patients who have chronic inflammatory diseases, such as rheumatoid arthritis, by potentially lowering the risk of infections, a common side effect of other anti-inflammatory drugs," Isis says. A phase II study is underway. (PR) Comment! [Healthcare]
- Thursday, February 28, 8:33 AM ISIS Pharmaceuticals (ISIS): Q4 EPS of -$0.03. Revenue of $19.9M beats by $4.12M. (PR) 3 Comments [Earnings, Breaking News, Healthcare]
- Thursday, February 28, 12:05 AM Notable earnings before Thursday’s open: AIXG, AWR, BDBD, BKS, BRLI, BRY, CHS, CTRX, CVC, DANG, DPZ, GMXR, GTLS, HK, IRDM, IRM, ISIS, KSS, LKQ, MCGC, MTG, NIHD, OCN, PKT, RDC, RNO, SDRL, SHLD, TD, TTI, VRX, WNR, WPX, WWE Comment! [Earnings]
- Wednesday, February 27, 5:30 PM Notable earnings before Thursday’s open: AIXG, AWR, BDBD, BKS, BRLI, BRY, CHS, CTRX, CVC, DANG, DPZ, GMXR, GTLS, HK, IRDM, IRM, ISIS, KSS, LKQ, MCGC, MTG, NIHD, OCN, PKT, RDC, RNO, SDRL, SHLD, TD, TTI, VRX, WNR, WPX, WWE Comment! [Earnings]
- Tuesday, February 19, 12:00 PM Isis Pharmaceuticals (ISIS +0.6%) says it's triggered a $7.5M milestone payment from GlaxoSmithKline (GSK) related to the initiation of a Phase 2/3 clinical study for ISIS-TTR, an antisense drug for treating transthyretin amyloidosis, a severe and rare genetic disease characterized by progressive dysfunction of peripheral nerve and/or heart tissues. Comment! [Healthcare]
-
Wednesday, January 30, 9:10 AM
Premarket gainers: BIOC +20%. CPNO +18%. MGAM +15%. AVY +11%. CHK +11%. AMZN +9%. UIS +8%. ISIS +8%. GEVO +5%.
Losers: GOL -6%. WBSN -5%. 1 Comment [On the Move]
Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.